The size of the worldwide market for bulimia nervosa treatments was estimated at USD 500 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 5.0% to reach approximately USD 800 million in 2030.
An eating disorder called bulimia nervosa is typified by periods of binge eating that are followed by purging activities including self-inflicted vomiting, overindulgent exercise, or improper use of laxatives or diuretics. Medical, psychological, and dietary therapies are often part of a multidisciplinary treatment plan for bulimia nervosa.
Treating the physical, emotional, and psychological components of bulimia nervosa is the main objective of the disorder’s care. The goal of medical therapies for bulimia is to treat any gastrointestinal problems or electrolyte imbalances that may result from the disorder. The underlying ideas, feelings, and behaviors linked to bulimia are the focus of psychological interventions such dialectical behavior therapy, interpersonal psychotherapy, and cognitive-behavioral therapy (CBT). The main goals of nutritional interventions are to teach people about good nutrition, encourage them to make healthy food choices, and help them create regular eating routines.
Request a sample copy of the report – https://wemarketresearch.com/sample-request/bulimia-nervosa-treatment-market/917
Key Company
Some of the prominent firms involved in the global bulimia nervosa treatment market are:
- AstraZeneca plc
- Sun Pharmaceutical Industries Ltd
- GSK plc
- Eli Lilly & Company
- Bayer AG
- Zydus Cadila
- Dr. Reddy’s Laboratories Limited
- Pfizer Inc.
- Sorrento Therapeutics, Inc.
- Johnson & Johnson
- Lupin limited
Bulimia Nervosa Treatment Market Key Trend
The disorder, bulimia nervosa, affects more women than men. In the United States, the disease has a lifetime prevalence rate of 0.5% in men and 1.5% in women, accounting for around 1.5 million men and 4.5 million women. Such high prevalence rates in women are projected to benefit the global bulimia nervosa treatment market over the evaluation period of 2020 to 2030.
Increased alcohol consumption, combined with an increase in the number of cardiovascular disease cases, is expected to benefit the global bulimia nervosa treatment market between 2020 and 2030. However, the high cost of therapy, as well as the lack of specialized and effective medications, are anticipated to restrict the rise of the worldwide bulimia nervosa treatment market in the coming years.
The COVID-19 pandemic is expected to have a negative impact on market growth in the near future. According to the Indian Journal of Medical Sciences, the pandemic has hampered clinical trials due to a paucity of trial site staff, a scarcity of investigational items, and travel limitations.
Market Dynamics
The global bulimia nervosa treatment market was much larger in 2021, and it is predicted to grow at a quick revenue CAGR over the forecast period. The rising prevalence of eating disorders among the elderly, as well as enhanced research and development to produce innovative therapies, are likely to drive revenue growth in the global bulimia nervosa treatment market. Furthermore, the scarcity of real and approved drugs for the treatment of bulimia nervosa is a major impediment to revenue growth in the bulimia nervosa treatment market.
The severe eating disorder known as bulimia nervosa, or just “bulimia,” can be lethal. Bulimics may discreetly overindulge and purge in an effort to burn off the extra calories in an unfavorable manner. The definition of bingeing is eating large amounts of food without exercising self control. Bulimia nervosa symptoms include an obsession with weight and body type, fear of gaining weight, forcing oneself to vomit or exercising excessively to prevent weight gain after bingeing, eating abnormally large amounts of food in one sitting on multiple occasions, and using laxatives, diuretics, or enemas after eating.
Bulimia Nervosa Treatment Market Opportunities
The market’s revenue growth is being driven by an increase in pharmaceutical research and development efforts for the more advanced treatment of bulimia nervosa. It is also anticipated that the industry will grow as a result of growing government involvement and global healthcare service improvement initiatives. Every patient has different symptoms, so each patient can have a customized course of treatment. Scientists and inventors can take advantage of this to develop a drug that works for bulimia nervosa sufferers in order to sustain revenue growth.
Buy Now Bulimia Nervosa Treatment Market Report – https://wemarketresearch.com/purchase/bulimia-nervosa-treatment-market/917?license=single
About We Market Research
We Market Research is a leading provider of comprehensive market research solutions that assist businesses in making informed decisions and staying ahead of the competition in today’s ever-changing marketplace. With our extensive knowledge and cutting-edge methods, we assist our customers in gaining deep insights into their target markets, consumers, and competitors.
Our firm understands that great business strategies are based on accurate and actionable data. That is why we specialize in conducting in-depth research and analysis across several industries, enabling our clients to identify market trends, assess demand and supply dynamics, and identify development opportunities.
Contact us
Mr. Robbin Joseph
Corporate Sales, USA
We Market Research
USA: +1-724-618-3925
Websites: https://wemarketresearch.com/
Email: [email protected]
